Hey everyone, it's Jennifer Jones, Enterprise Practice Leader with Springbuk.
Well, we are in the thick of conference season. And if you're anything like us, it feels like you have sat through hundreds of sessions by now. But one thing we all have realized is that we have two emerging concepts from most of these sessions:
- Everyone is struggling to find an unbiased way to show impact and outcomes with their point solutions.
- It is incredibly challenging for employers to be able to identify the impact that biosimilars could potentially have on their overall spend.
So let's take a look at each of these.
Related to point solutions, we know that there is no lack of options in the market for all of you. Now while many of these do provide great benefits, not only for you and your members but also for their families – we know you are also bombarded with opportunities on a daily basis.
But, you need to be able to measure the impact of these points solutions and really understand how you can best optimize your current benefit offerings.
So let me say: we hear you.
That's why, at Springbuk, we take a thoughtful and strategic approach when working with point solutions and your ancillary data. We work with each vendor individually and collaboratively. And we take a 'trust but verify approach' to the data and reports they're already providing you to ensure we can have an apples-to-apples comparison.
We then integrate the point solution data with your medical and Rx claims and expand and develop a comprehensive view of outcomes and impact that can include different opportunities, as we think about cost utilization, various clinical outcomes, engagement, and even satisfaction.
This is what we call integrated analytics - it puts you in control of your data and allows you to make smarter, data-informed decisions.
Now, onto concept number two.
Specialty drugs continue to have a disproportionate percentage of healthcare spend. And with the release of some recent biosimilar drugs to the market, we hope that we can see an improvement of this.
But the struggle is real for many employers as you're trying to find answers, like:
- How soon can you expect an impact?
- How much savings should you expect?
- How do you know you can get members on a biosimilar?
I personally attended a great session where an employer ran their own study on their data by using existing methodologies and research to be able to find those answers to those questions.
But we know your time and resources are limited, and that's why we do the heavy lifting for you.
Our Insights page provides our clients with curated, actionable opportunities of how many members are eligible for biosimilars. And if there are potential cost savings by shifting the site of care of where they receive their specialty infusions.
We also love research, and our Employee Health Trends Report provides a tremendous overview on the historical use and adoption rate of biosimilars, both via the medical channel and the Rx channel, which allows our readers and our users to set expectations on what we should expect with the new biosimilars coming to market.
If you're still with me, we'd love to connect and answer any questions that you have, so feel free to connect with me via LinkedIn.
Jennifer Jones, MSM RD, Enterprise Market Leader
Jennifer Jones, MSM, RD, is an experienced healthcare professional with a background in clinical dietetics, wellness programming, and employer health, and is a certified Corporate Wellness Specialist.
With over 20 years of experience, she has worked in various settings including health care systems, occupational health organizations, and a health and welfare benefits advisory firm. After working directly with patients and employees, Jennifer turned her focus to population and employer health to achieve a greater impact on health outcomes.